Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
1.710
-0.020 (-1.16%)
Mar 26, 2026, 11:54 AM EDT - Market open
Cardiff Oncology Employees
As of December 31, 2025, Cardiff Oncology had 31 total employees, including 30 full-time and 1 part-time employees. The number of employees decreased by 2 or -6.06% compared to the previous year.
Employees
31
Change (1Y)
-2
Growth (1Y)
-6.06%
Revenue / Employee
$19,129
Profits / Employee
-$1,479,871
Market Cap
116.90M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 31 | -2 | -6.06% | 30 | 1 |
| Dec 31, 2024 | 33 | 1 | 3.13% | 32 | 1 |
| Dec 31, 2023 | 32 | 6 | 23.08% | 31 | 1 |
| Dec 31, 2022 | 26 | 3 | 13.04% | 25 | 1 |
| Dec 31, 2021 | 23 | 11 | 91.67% | 22 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Karyopharm Therapeutics | 228 |
| Sangamo Therapeutics | 183 |
| Innate Pharma | 174 |
| Vor Biopharma | 154 |
| Inovio Pharmaceuticals | 112 |
| Artiva Biotherapeutics | 104 |
| Equillium | 35 |
| Spero Therapeutics | 32 |
CRDF News
- 5 hours ago - Cardiff Oncology, Inc. (CRDF) Discusses Advances in First-Line Treatment for RAS-Mutated Metastatic Colorectal Cancer and Clinical Data on PLK1 Inhibitor Transcript - Seeking Alpha
- 6 days ago - Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer - GlobeNewsWire
- 7 days ago - Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting - GlobeNewsWire
- 27 days ago - Cardiff Oncology to Participate in Three Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - Cardiff Oncology to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 2 months ago - Cardiff Oncology Stock Plunges After Sudden Leadership Change, Narrowed Trial Focus - Benzinga
- 2 months ago - Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC Transcript - Seeking Alpha